Background and Rationale
In patients with acute pulmonary embolism (PE), the risk of early death or haemodynamic collapse ranges from less than 1 to over 50%, depending on the severity of the acute episode as well as the cardiopulmonary reserves and comorbidity of the patient.
1-3 Current European clinical practice guidelines place particular emphasis on early risk stratification to determine the optimal risk-adjusted treatment strategy. Patients with haemodynamic compromise or frank cardiogenic shock at presentation have at least 20% risk of early adverse events and should receive immediate reperfusion therapy, while those with low-risk PE, as defined in the 2014 Guidelines of the European Society of Cardiology (ESC 2 ), and no other indication for hospitalization should be considered for early discharge and home treatment. [4] [5] [6] [7] [8] The remaining patients with acute PE are classified into the intermediaterisk category and depending on the method and the cut-off values used for definition, they may account for up to 60% of all PE patients and have up to 7.7% risk of early mortality.
2,9
The prognostic impact and therapeutic implications of intermediate-risk PE, and particularly the 'upper zone' of severity within this category, were highlighted by the results of the Pulmonary Embolism International Thrombolysis (PEITHO) trial. 10 In the placebo (heparin-only) arm of PEITHO, the upper limit of the 95% confidence interval (CI) for the risk of haemodynamic decompensation was as high as 8% (mean 5.6%) in normotensive patients who presented both with right ventricular dysfunction on echocardiography or computed tomographic pulmonary angiography (CTPA), and with evidence of myocardial injury indicated by elevated cardiac troponin levels.
10
Historically, the standard therapeutic regimen for patients with acute PE has consisted of parenteral anticoagulation (intravenous unfractionated heparin, or subcutaneous lowmolecular-weight heparin [LMWH] or fondaparinux) with overlapping administration of a vitamin K antagonist (VKA) until reaching a therapeutic range of the international normalized ratio (INR). 2 More recently, four non-vitamin K-dependent direct oral anticoagulants (NOACs), that is, one direct thrombin inhibitor (dabigatran) and three factor Xa inhibitors (rivaroxaban, apixaban and edoxaban) were demonstrated to be non-inferior and at least as safe as traditional treatment with LMWH and VKA, and subsequently approved for the treatment and secondary prevention of venous thromboembolism (VTE). over the first 72 hours, followed by the direct oral thrombin inhibitor dabigatran over 6 months, is effective and safe. The primary efficacy outcome is recurrent symptomatic venous thromboembolism or death related to PE within the first 6 months. The primary safety outcome is major bleeding as defined by the International Society on Thrombosis and Haemostasis. Secondary outcomes include all-cause mortality, the overall duration of hospital stay (index event and repeated hospitalizations) and the temporal pattern of recovery of right ventricular function over the 6-month follow-up period. By applying and evaluating a contemporary risk-tailored treatment strategy for acute PE, PEITHO-2 will implement the recommendations of current guidelines and contribute to their further evolution.
acute intermediate-risk PE was in all but one of the phase III studies mentioned earlier.
11-14
The Hokusai-VTE phase III trial reported data for the subgroup of patients with acute PE and right ventricular (RV) dysfunction, defined as right-to-left ventricular (RV/LV) diameter ratio !0.9 on CT angiography, and for patients with N-terminal pro-brain natriuretic peptid (NT-proBNP) levels greater than 500 pg/mL. Dabigatran is an already approved agent for the treatment of patients with acute PE, without excluding those with intermediate-risk PE. Although it is unknown how many of the patients included in the dabigatran phase III RECOVER trials belonged to the latter risk category, the members of the PEITHO-2 steering committee agreed that it would be inappropriate to repeat the randomized design of the RECOVER trials (dabigatran vs. VKA) within this focused study population. Instead, it is planned to analyse the data from PEITHO-2, upon completion, against the patient-level data from either treatment arm (dabigatran vs. warfarin) of the pooled RECOVER population.
11 This will allow us to compare the efficacy and safety of dabigatran in the present trial with (1) the efficacy and safety of the same drug in the 'unselected'
(with regard to severity) PE subpopulation of RECOVER (dabigatran arm) and (2) 2 ) within the present trial will be determined. The data will then be compared with the 6-month follow-up data from a corresponding subgroup, which will be selected on a patient-level basis from the placebo (heparin followed by VKA) arm of the PEITHO randomized controlled trial (unpublished data). Considering all the above, we believe that the single-arm design of PEITHO-2 will allow us to successfully put the results of PEITHO-2 into perspective, while also fulfilling an important ethical requirement, namely keeping the number of patients and the complexity as well as the duration of the trial to the minimum required for adequately answering the study questions. This rationale was endorsed by the trial's central ethics committee in Germany and by the ethics committees of the countries in which the trial is already recruiting.
Patient Population and Eligibility
The key inclusion and exclusion criteria are summarized in ►Table 2. Patients with symptomatic acute, intermediaterisk PE, diagnosed by multidetector CT angiography, ventilation/perfusion lung scan or selective invasive pulmonary angiography, with or without symptomatic DVT, who are haemodynamically stable at presentation, are eligible for enrolment in the study. The diagnosis of intermediate-risk PE is confirmed at each participating site, based on standardized diagnostic and risk stratification criteria and as recommended in current guidelines.
2
In contrast to Hokusai-VTE, 12,15 PEITHO-2 uses the more practical and 'intuitive' 1.0 threshold for defining an abnormally high RV/LV ratio, in agreement with other interventional trials 10, 18 and cohort studies [19] [20] [21] in haemodynamically stable patients with acute PE. Furthermore, the threshold of 600 pg/mL is used in the inclusion criterion involving the biomarker NT-proBNP, as we have previously reported that this may be the most appropriate value for defining intermediate risk.
22-24
Current guidelines include the Pulmonary Embolism Severity Index (PESI) in the definition of intermediate-risk PE. However, despite the prognostic value of the PESI, 25 it should be kept in mind that it was primarily designed as an epidemiological tool and not as a direct guide to PE management. Moreover, it has been reported that (severe) RV dysfunction may be present despite a simplified PESI of 0. 26 If reproduced, this would be a relevant finding that could change future risk stratification algorithms. For these reasons, the present study does not use the simplified PESI as an inclusion criterion. Importantly, however, the index is prospectively calculated and documented in all patients, and it will thus be possible to determine if and how many study patients may exhibit a discordance between the clinical score and their imaging or biochemical parameters at presentation.
Treatment Regimen
In the RECOVER trials, the median duration of initial parenteral treatment with LMWH was 9 days. 11, 17 This was longer than the current average duration of hospitalization of patients with PE in Europe and North America, which generally does not exceed 4 to 6 days. 27, 28 Longer treatment periods with a parenteral anticoagulant before switching to an NOAC might delay the discharge of stable patients and thus increase treatment-related costs. Therefore, in this study, we are investigating the approach of an earlier switch from parenteral anticoagulants to dabigatran in clinically stabilized intermediate-risk PE patients. The study flow is summarized in ►Fig. 1. After enrolment, patients start or continue to receive LMWH at a therapeutic dosage for a period of 72 hours from the moment of PE diagnosis. If LMWH is not available, treatment with unfractionated heparin given by intravenous infusion is acceptable. The 72-hour duration of parenteral anticoagulation was chosen based on our previous PEITHO trial, 10 in which the vast majority of early adverse outcomes (and thus cases of possible need for switch to rescue reperfusion therapy) in patients with intermediate-high-risk PE occurred within the first 3 days of randomization (unpublished data). Thereafter, and following clinical assessment of the patient's condition, treatment is switched to oral dabigatran at the dosage of 150 mg twice daily. A reduced dose of 110 mg twice daily is recommended for patients aged 80 years or older, and for those under concomitant treatment with verapamil, according to the European Summary of Product Characteristics (SmPC) for dabigatran. The switch from LMWH to dabigatran is postponed by the investigator if (1) the patient is in shock, or haemodynamic collapse is considered imminent in view of deteriorating clinical parameters such as tachycardia, hypotension or dyspnoea and hypoxaemia; (2) the patient has received thrombolytic, surgical or catheter-directed treatment, or underwent cava filter implantation within the past 48 hours; (3) there is active bleeding or (4) the patient is, for Dabigatran for the Treatment of Acute Intermediate-Risk Pulmonary Embolism Klok et al. 2429
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any other reason, unable to receive oral anticoagulation. If at least one of these criteria is present, LMWH is continued and the eligibility for switching to dabigatran treatment is reassessed 48 hours later. Of note, the diagnostic workup and management of patients with early haemodynamic deterioration is based on local hospital protocols and the recommendations of current guidelines, and not dictated by the trial protocol.
Oral anticoagulation with dabigatran is continued for 6 months. An overview of the tests performed and the parameters collected upon enrolment and at the followup visits is provided in ►Table 3. After the end of the study period, the decision on whether to continue anticoagulation treatment, and which anticoagulant drug to administer, is left to the discretion of the physician(s) caring for the patient.
Outcomes ►Table 4 summarizes the outcomes of the PEITHO-2 trial. The primary efficacy outcome is the occurrence of recurrent symptomatic VTE or death related to PE within 6 months of therapy. Recurrent symptomatic DVT is confirmed by a new non-compressible venous segment on compression ultrasonography or by a new filling defect on CT venography. Recurrent symptomatic PE is diagnosed by a new filling defect on CT pulmonary angiography, or by a more proximal Table 3 Trial visit plan and data collection schedule obstruction of a previously occluded pulmonary artery, or by a new segmental mismatch on ventilation-perfusion lung scan. Death related to PE is defined as death following acute, objectively confirmed symptomatic recurrent PE or as sudden death not explained by another cause. The safety outcomes include major bleeding, 29 non-major clinically relevant bleeding and occurrence of serious adverse events (►Table 4). In addition, the recently developed and validated VTE-BLEED score will be prospectively evaluated with respect to its ability to predict bleeding events.
30-32
The management of patients with severe haemorrhagic complications under anticoagulant treatment is based on local hospital protocols and the recommendations of current guidelines and consensus statements. 33, 34 It is not dictated by the protocol of the present trial. All primary and secondary outcomes will be adjudicated by an independent committee, the members of which are mentioned in the ►Appendix A.
Sample Size Calculation and Statistical Analysis Plan
The expected incidence of the primary outcome of the present study is derived from data provided by Hokusai-VTE and PEITHO. 10, 12 Considering the definition of RV dysfunction in Hokusai-VTE, and the inclusion criteria of PEITHO (focusing on intermediate-high risk), we assumed that, in PEITHO-2, the incidence rate of the primary outcome in the total study population of 'unselected' intermediate-risk PE will be at least as high and possibly higher than that of the Hokusai study (3.3%), but it will not exceed the point estimate of that in the 6-month follow-up of the 'intermediate-high-risk' PEITHO trial (6.1%). Thus, assuming a 3.3%
incidence of the primary outcome, we will test the null hypothesis (H 0 ; probability [p] ! 0.061; 6.1%) against the alternative hypothesis (H 1 ; p < 0.061) using a one-sided exact binomial test in a two-stage Pocock group sequential design. The significance level was chosen as α ¼ 5%, leading to a nominal α ¼ 0.003037 at the first stage. It is expected that 650 patients will provide a power of 90% for rejecting H 0 (p ! 0.061) at the final stage if p is indeed 0.033. Taking into account a loss to follow-up of 7% maximum, a total number of 700 patients will have to be enrolled in PEITHO-2. All analyses will be performed in the intention-to-treat population. We will consider our hypothesis that treatment with dabigatran preceded by at least 72 hours of parental anticoagulation is an effective treatment for patients with acute intermediate-risk PE as proven if the null hypothesis can be rejected, that is if 27 or less events are observed among 650 analysed patients.
A formal interim analysis is planned after 20% of the targeted patient population has been included and followed for 30 days. We will consider more than 11 events as an indication that it is no longer realistic to reject H 0 in the further course of the trial, as the conditional power to reject the null hypothesis would then be below 50%. In this case, the Data Safety Monitoring Board may propose a protocol amendment that dictates that the switch from parenteral anticoagulants to dabigatran should be delayed to 5 AE 1 days in all patients.
Subgroups will be analysed with regard to the following outcomes: (1) primary outcome; (2) death or haemodynamic collapse or decompensation from any cause, PE-related death or haemodynamic collapse or decompensation, within the Non-major clinically relevant bleeding defined as:
• Spontaneous skin haematoma of at least 25 cm first 30 days; (3) overall duration of hospital stay within 6 months; (4) death from any cause within 6 months and (5) all safety outcomes (►Table 4). The prespecified variables and cut-offs for defining patient subgroups are the following: age (<75 vs. !75 years), sex, provoked versus unprovoked PE, patients with versus patients without cancer, presence versus absence of symptomatic confirmed DVT, patients with sPESI of 0 versus 1 or higher at baseline, intermediate-low-risk versus intermediate-high-risk PE, baseline NT-proBNP ( 600 vs. >600 pg/mL), switch to dabigatran after 72 hours versus switch after 5 days or later, echocardiographically assessed cardiac recovery versus no recovery and NT-proBNP levels (normalization vs. improvement vs. no improvement vs. deterioration). Finally, the rates of the primary efficacy outcome and major bleeding in the study population will be compared with those in either treatment arm (dabigatran or warfarin) of the pooled RECOVER population. 11 In addition, the rates of the primary outcome and major bleeding in the predefined intermediate-high-risk subgroup of patients enrolled in the present trial will be compared with those in the placebo (heparin followed by VKA) arm of the PEITHO randomized controlled trial at 6-month follow-up.
Current Enrolment Status
As with the already available data from PEITHO will help put the efficacy and safety of the PEITHO-2 strategy into perspective.
With the same objective, the results of PEITHO-2 will be compared with those from the phase III RECOVER trials with dabigatran, although possible differences in the clinical severity of PE, and the (expected) shorter duration of initial heparin anticoagulation in the present study, might pose some limitations in this regard.
If the hypothesis of PEITHO-2 is confirmed, patients with intermediate-risk PE will need only 72 hours of parenteral heparin treatment before switching to oral anticoagulation. This may offer the potential to safely reduce the duration of hospitalization for PE, with an impact on hospital-related complication rates, morbidity and costs. On the other hand, the PEITHO-2 study will also be able to determine which patients within the broad spectrum covered by intermediate-risk PE might need a more conservative approach with longer periods of parenteral heparin treatment. Finally, with its comprehensive follow-up strategy, the PEITHO-2 study will provide a deeper insight into RV recovery after acute PE, and its implications for the long-term prognosis of the patients.
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